Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379981 | 0.88 | LIPG (0.42) | LIPGLPLIRAK4ROCK1BACE1 | |
| SCHEMBL25965934 | 0.85 | LIPG (0.40) | LIPGLPLIRAK4ROCK1BACE1 | |
| SCHEMBL19464248 | 0.82 | LIPG (0.42) | LIPGLPLIRAK4ROCK1BACE1 | |
| SCHEMBL14321414 | 0.81 | HSD17B10 (0.41) | LIPGLPLIRAK4ROCK1 | |
| SCHEMBL14321412 | 0.81 | HSD17B10 (0.41) | LIPGLPLIRAK4ROCK1 | |
| SCHEMBL14321849 | 0.80 | LIPG (0.40) | LIPGLPLIRAK4ROCK1BACE1 | |
| SCHEMBL14332527 | 0.80 | LGMN (0.42) | LIPGLPLIRAK4ROCK1 | |
| SCHEMBL19463321 | 0.79 | LIPG (0.39) | LIPGLPLIRAK4ROCK1BACE1 | |
| SCHEMBL17027126 | 0.78 | NOTUM (0.46) | LIPGLPLROCK1 | |
| SCHEMBL1726528 | 0.77 | LPL (0.44) | LIPGLPLIRAK4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | LIPG 4267/4885LPL 4661/4885IRAK4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.